ArticleImmunity2019
MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells.
Abstract read
In one paragraph
Article in Immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Expression and Regulatory Mechanisms of MicroRNA in Cholesteatoma: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- DRP1 depletion protects NK cells from hypoxia-induced dysfunction.Redox report : communications in free radical research · 2026Article
- Exosomal circPDSS1 Derived From Gastric Cancer Cells Promotes Natural Killer Cell Ferroptosis by Regulating the miR-142-3p/ACSL4 Molecular Axis.Applied biochemistry and biotechnology · 2026Article
- Article
- miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.Nature communications · 2025Article
- MicroRNA-142 regulates gut associated lymphoid tissues and group 3 innate lymphoid cells.Mucosal immunology · 2025Article
- Protein swarm-based cause-effect analysis: effects of microRNAs on cooperation networks linking COVID-19 infections, atherosclerosis, and Alzheimer's disease.Frontiers in cardiovascular medicine · 2025Article
- MicroRNA-146a deficiency enhances host protection against murine cytomegalovirus.European journal of immunology · 2024Article
- DNA demethylase Tet2 promotes the terminal maturation of natural killer cells.Immunologic research · 2024Article
- MicroRNA-focused CRISPR/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation.PLoS pathogens · 2024Article
- miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.Cells · 2023Review
- MicroRNAs: Small but Key Players in Viral Infections and Immune Responses to Viral Pathogens.Biology · 2023Review
- Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis.Nature communications · 2023Article
- Regulation of noncoding RNAs in innate lymphoid cells.Cellular & molecular immunology · 2023Article
- Article
- Review
- Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.Scientific reports · 2022Article
- Review
- MicroRNAs in shaping the resolution phase of inflammation.Seminars in cell & developmental biology · 2022Review
- miRNome Profiling Detects miR-101-3p and miR-142-5p as Putative Blood Biomarkers of Frailty Syndrome.Genes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Melissa M Berrien-ElliottDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Yaping SunDivision of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Carly NealDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Aaron IrelandDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Maria C TrissalDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Ryan P SullivanDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Julia A WagnerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Jeffrey W LeongDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Pamela WongDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Annelise Y Mah-SomDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, USA.
Terrence N WongDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Timothy SchappeDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Catherine R KeppelDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Victor S CortezDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.
Efstathios G StamatiadesImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ming O LiImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.
Daniel C LinkDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Anthony R FrenchDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, USA.
Megan A CooperDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, USA.
Wei-Le WangDepartment of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Mark P BoldinDepartment of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Pavan ReddyDivision of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Todd A FehnigerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA. Electronic address: tfehnige@wustl.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8MSpecimen Acquistition and Expression ProfilingP01CA101937 · NCI · WASHINGTON UNIVERSITY · PI LEY, TIMOTHY J. · 2003 to 2023
$58.8MTargeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI TODD A FEHNIGER · 2013 to 2026
$31.6MPRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGYT32HL007088 · NHLBI · WASHINGTON UNIVERSITY · PI Grant Anthony Challen, Stephen Oh · 1985 to 2026
$14.1MTRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCERT32CA009547 · NCI · WASHINGTON UNIVERSITY · PI ROBERT DAVID SCHREIBER · 1986 to 2026
$12.1MMucosal Immune Defense Mechanisms of the Urinary BladderU01AI095542 · NIAID · WASHINGTON UNIVERSITY · PI COLONNA, MARCO, HULTGREN, SCOTT J. · 2011 to 2020
$9.8MREGULATION OF VIRAL-INDUCED NK CELL PROLIFERATION DURING MURINE CMV INFECTIONR01AI078994 · NIAID · WASHINGTON UNIVERSITY · PI FRENCH, ANTHONY R · 2009 to 2019
$3.8MThe role of TGFbeta in development and function of salivary gland innate lymphoid cellsR01DE025884 · NIDCR · WASHINGTON UNIVERSITY · PI COLONNA, MARCO, WEISMAN, GARY ANDREW · 2017 to 2021
$3.5MTargeting antigen presentation to enhance GVL responses after Bone Marrow TransplR01HL090775 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2008 to 2016
$3.4MTRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPYR01CA205239 · NCI · WASHINGTON UNIVERSITY · PI FEHNIGER, TODD A · 2017 to 2020
$2.4MControl of B cell development and effector functions by microRNA-142R01AI125615 · NIAID · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BOLDIN, MARK P · 2016 to 2020
$2.1MHoward Hughes Medical InstituteNCI NIH HHS F32 CA200253NCI NIH HHS K08 CA197369NCI NIH HHS P01 CA101937NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA171963NCI NIH HHS R01 CA143379NCI NIH HHS R01 CA173878NCI NIH HHS R01 CA205239NCI NIH HHS T32 CA009547NHLBI NIH HHS R01 HL090775NHLBI NIH HHS T32 HL007088NIAID NIH HHS F30 AI129110NIAID NIH HHS R01 AI078994NIAID NIH HHS R01 AI102924NIAID NIH HHS R01 AI125615NIAID NIH HHS R01 AI127752NIAID NIH HHS R56 AI127752NIAID NIH HHS U01 AI095542NIDCR NIH HHS R01 DE025884NIDDK NIH HHS R01 DK103039NIGMS NIH HHS T32 GM007200
Abstract
Natural killer (NK) cells are cytotoxic type 1 innate lymphoid cells (ILCs) that defend against viruses and mediate anti-tumor responses, yet mechanisms controlling their development and function remain incompletely understood. We hypothesized that the abundantly expressed microRNA-142 (miR-142) is a critical regulator of type 1 ILC biology. Interleukin-15 (IL-15) signaling induced miR-142 expression, whereas global and ILC-specific miR-142-deficient mice exhibited a cell-intrinsic loss of NK cells. Death of NK cells resulted from diminished IL-15 receptor signaling within miR-142-deficient mice, likely via reduced suppressor of cytokine signaling-1 (Socs1) regulation by miR-142-5p. ILCs persisting in Mir142
Indexed as
AnimalsCell LineFemaleHEK293 CellsHomeostasisHumansImmunity, InnateKiller Cells, NaturalLymphocytesMaleMiceMice, Inbred BALB CMice, Inbred C57BLMicroRNAsMuromegalovirusNIH 3T3 CellsMicroRNAsMirn142 microRNA, mouseReceptors, Interleukin-15Suppressor of Cytokine Signaling ProteinsTransforming Growth Factor betacytokine receptorsIL-15ILC1-like cellsinnate lymphoid cellsintegrinmicroRNA-142murine cytomegalovirusNK cellstissue resident
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.